Role of clobetasol propionate 0.025% topical therapy in various dermatoses

Abstract

The anti-inflammatory and vasoconstrictive properties of topical corticosteroids (TCs) contribute in providing therapeutic benefits in several skin conditions, including atopic eczema, localized vitiligo, psoriasis, and chronic hand eczema. Clobetasol propionate (CP) is the most common topical agent used for psoriasis management and demonstrates an efficacy superior to other TCs. A new CP 0.025% cream formulation has demonstrated hypoallergenic effects due to the absence of known contact allergens, such as propylene glycol, short-chain alcohols, and sorbitol-based emulsifiers. Lower CP serum levels and less hypothalamic–pituitary–adrenal axis suppression with CP 0.025% cream formulation than with CP 0.05% ensure better safety. The present case series discusses the clinical experience of using CP 0.025% cream in various dermatological conditions.

Clobetasol propionate 0.025%: a topical therapeutic for skin diseases

“…The topical use of CP helps decrease inflammation and pruritis in atopic dermatitis and psoriasis. 3 The effectiveness, skin acceptability, and safety of CP 0.025% cream have been demonstrated in two pivotal, randomized, controlled trials. CP 0.025% cream has no typical contact allergies and uses diethylene glycol monoethyl ether to promote active ingredient penetration without causing systemic absorption.…”

“…The addition of pharmaceutical-grade diethylene glycol monoethyl ether to CP 0.025% significantly improves its effectiveness. 3 The effectiveness, safety, and clinical experience of employing CP 0.025% to treat diverse dermatoses are discussed in this case series.…”